文献速递银屑病与炎症性皮肤病

Risankizumab治疗中重度银屑病的真实世界有效性:CorEvitas银屑病登记研究

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry.
PubMed 文献 · J Am Acad Dermatol · 2023-09-20

基于CorEvitas银屑病登记的前瞻性观察性研究,纳入287例持续使用risankizumab满12(±3)个月的中重度斑块状银屑病成人患者,评估皮损清除与患者报告结局。多数患者达到皮损完全清除或几乎完全清除,DLQI评分及银屑病症状(疲劳、皮肤疼痛、整体瘙痒)和工作活动受损均显著降低。

要点

  • 287例持续用药1年者中多数达到皮损完全清除或几乎完全清除。
  • DLQI评分及疲劳、皮肤疼痛、整体瘙痒等症状显著降低。
  • 无论既往是否使用过生物制剂,患者均获得较高的皮损清除水平。

核心结论

  • risankizumab治疗1年后,无论既往治疗史如何,患者均获得高水平的皮损完全清除和几乎完全清除、DLQI评分0/1,以及银屑病症状和工作活动受损的显著降低。

研究设计与样本

  • 回顾性观察性研究,使用CorEvitas银屑病登记数据,纳入诊断为中重度银屑病且在启动risankizumab后12(±3)个月持续使用的合格成人患者。

主要发现

  • 287例患者在1年时持续使用risankizumab,多数达到皮损完全清除或几乎完全清除。
  • 患者报告DLQI评分显著降低,银屑病症状(疲劳、皮肤疼痛和整体瘙痒)及工作活动受损显著降低。
  • 分析涵盖整个研究人群并按既往生物制剂治疗史分层。

临床怎么用

  • 在真实世界临床实践中,risankizumab可用于中重度斑块状银屑病成人患者,包括既往接受过生物制剂治疗者。

局限性

  • CorEvitas银屑病登记不一定代表美国和加拿大所有银屑病成人患者。
  • 该登记不测量患者依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis, an inflammatory skin disease, is often treated with biologic therapeutics. OBJECTIVE: To determine the real-world treatment effectiveness of risankizumab, an interleukin-23 inhibitor, in the treatment of moderate-to-severe plaque psoriasis. METHODS: A retrospective, observational study was conducted using the CorEvitas Psoriasis Registry for eligible adults with a diagnosis of moderate-to-severe psoriasis and persistent use of risankizumab at 12 (±3) months after initiation. Skin clearance measures and patient-reported outcomes were analyzed for the entire study population and by prior biologic treatment. RESULTS: Among 287 patients with persistent risankizumab use at 1 year, most achieved clear or clear/almost clear skin and reported significant reductions in Dermatology Life Quality Index scores, psoriasis symptoms (fatigue, skin pain, and overall itch), and work and activity impairment. LIMITATIONS: The CorEvitas Psoriasis Registry is not necessarily representative of all adults with psoriasis in the United States and Canada and does not measure patient adherence. CONCLUSION: Patients treated with risankizumab, regardless of prior treatment, achieved high levels of clear and clear/almost clear skin, Dermatology Life Quality Index scores of 0/1, and significant reductions in psoriasis symptoms (fatigue, skin pain, and overall itch) and work and activity impairment 1 year after initiation.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Ferris L, Callis Duffin K, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2023. PMID: 37739267. doi:10.1016/j.jaad.2023.08.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。